Pure Global
NCT06256198

Role of PCO2 Gap as Predictor of Clinical Outcome in ICU Septic Patients

Comparison Between PCO2 Gap, Lactate and Procalcitonin as Predictors of Clinical Outcome in ICU Septic Patients
Ain Shams University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis
Drug/Device/Intervention
measurement of serum lactate and procalcitonin and PCO2 gap
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Ain Shams University
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Jun 01, 2024
Enrollment
80 participants
Primary outcome

prediction of clinical outcome in ICU septic patients

Summary

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to
 infection, if not recognized early and managed promptly, it can lead to septic shock,
 multiple organ failure and death. Sepsis is associated with high mortality, and the early
 recognition of the signs of tissue hypo perfusion is crucial in its management.
 
 This prospective study was aimed to detect that PCO2 gap can be taken as a reliable
 prognostic tool in septic patients

ICD-10 classifications
Other sepsisSepsis, unspecifiedOther specified sepsisCandidal sepsisPuerperal sepsis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06256198
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06256198 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Not yet recruiting. The study focuses on Sepsis. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.